Topicort is owned by Taro Pharms.
Topicort contains Desoximetasone.
Topicort has a total of 2 drug patents out of which 0 drug patents have expired.
Topicort was authorised for market use on 11 April, 2013.
Topicort is available in spray;topical dosage forms.
Topicort can be used as treatment of plaque psoriasis in patients 18 years of age or older.
The generics of Topicort are possible to be released after 01 September, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8715624||TARO PHARMS||Stable liquid desoximethasone compositions with reduced oxidized impurity|| |
(3 years from now)
|US8277780||TARO PHARMS||Stable liquid desoximethasone compositions with reduced oxidized impurity|| |
(5 years from now)
Market Authorisation Date: 11 April, 2013
Treatment: Treatment of plaque psoriasis in patients 18 years of age or older
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic